Nuzhat A. Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nuzhat A. Ahmad has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Gregory G. Ginsberg
University of Pennsylvania
20 shared publications - Michael L. Kochman
Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
19 shared publications - Vinay Chandrasekhara
Division of Gastroenterology, Mayo Clinic, Rochester, MN
17 shared publications - Gene K. Ma
From University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
7 shared publications Nikhil Thiruvengadam
6 shared publicationsDavid L. Jaffe
5 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB423
Mo1270 THE ROLE OF EUS-GUIDED TISSUE ACQUISITION FOR GENOMIC ANALYSIS OF PANCREATIC ADENOCARCINOMA: IMPLICATIONS FOR PERSONALIZED MEDICINE
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB423
Mo1270 THE ROLE OF EUS-GUIDED TISSUE ACQUISITION FOR GENOMIC ANALYSIS OF PANCREATIC ADENOCARCINOMA: IMPLICATIONS FOR PERSONALIZED MEDICINE
- 23 October 2017
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 15 (4) , 587-602
Diagnosis and Management of Pancreatic Cystic Neoplasms
Opinion statement Pancreatic cystic neoplasms (PCNs) are being diagnosed with increasing frequency. PCNs have diverse presentations, natural history, and biological behavior. Obtaining an accurate diagnosis of the type of cyst and assessing the potential for malignancy are crucial in determining the appropriate management strategy. Cross-sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI), at experienced centers, is effective in defining the type of cyst as well as identifying high-risk features. Endoscopic ultrasound with fine-needle aspiration (EUS-FNA) and cyst fluid analysis can categorize and risk-stratify cysts and is the test of choice in selected patients. However, there is currently no “perfect” test and studies have demonstrated substantial misdiagnosis and over-treatment of benign cysts using standard clinical, imaging, and cyst fluid analyses. Patients with symptomatic cysts or cysts with high-risk features suggestive of malignancy should be considered for surgical resection. Patients with low-risk PCNs can be placed in surveillance protocols with interval imaging. Various gastrointestinal societies have put forth evidence- or consensus-based guidelines that provide a framework for management of PCNs. However, the management can be complex and should ideally be planned in a multidisciplinary fashion by experienced specialists. Recent investigations using molecular markers to risk-stratify cysts offer promise in the future for an effective and accurate management strategy.
- 23 October 2017
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 15 (4) , 587-602
Diagnosis and Management of Pancreatic Cystic Neoplasms
Opinion statement Pancreatic cystic neoplasms (PCNs) are being diagnosed with increasing frequency. PCNs have diverse presentations, natural history, and biological behavior. Obtaining an accurate diagnosis of the type of cyst and assessing the potential for malignancy are crucial in determining the appropriate management strategy. Cross-sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI), at experienced centers, is effective in defining the type of cyst as well as identifying high-risk features. Endoscopic ultrasound with fine-needle aspiration (EUS-FNA) and cyst fluid analysis can categorize and risk-stratify cysts and is the test of choice in selected patients. However, there is currently no “perfect” test and studies have demonstrated substantial misdiagnosis and over-treatment of benign cysts using standard clinical, imaging, and cyst fluid analyses. Patients with symptomatic cysts or cysts with high-risk features suggestive of malignancy should be considered for surgical resection. Patients with low-risk PCNs can be placed in surveillance protocols with interval imaging. Various gastrointestinal societies have put forth evidence- or consensus-based guidelines that provide a framework for management of PCNs. However, the management can be complex and should ideally be planned in a multidisciplinary fashion by experienced specialists. Recent investigations using molecular markers to risk-stratify cysts offer promise in the future for an effective and accurate management strategy.
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB398-AB399
Su1694 Incidence and Risk Factors for Advanced Neoplasia After Endoscopic Mucosal Resection of Colonic Polyps
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB398-AB399
Su1694 Incidence and Risk Factors for Advanced Neoplasia After Endoscopic Mucosal Resection of Colonic Polyps
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB561
Tu1159 Long Term Outcomes of Multiband Mucosectomy for Dysplastic Barrett's
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB561
Tu1159 Long Term Outcomes of Multiband Mucosectomy for Dysplastic Barrett's
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S672
Prediction of Advanced Neoplasia in Pancreatic Cystic Neoplasms: A Validated Risk Score
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S672
Prediction of Advanced Neoplasia in Pancreatic Cystic Neoplasms: A Validated Risk Score
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S219-S220
Gastrointestinal Bleeding in Inpatients Admitted for Another Indication: Results of a Multi-Center Retrospective Analysis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S219-S220
Gastrointestinal Bleeding in Inpatients Admitted for Another Indication: Results of a Multi-Center Retrospective Analysis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S673-S674
Recurrence Rates after Surgical Resection of Patients with Intraductal Papillary Mucinous Neoplasms: A Single Center Experience
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S673-S674
Recurrence Rates after Surgical Resection of Patients with Intraductal Papillary Mucinous Neoplasms: A Single Center Experience
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S225
Real-Time Communication of a Clinical Pathway for Upper Gastrointestinal Bleeding through Secure Text Messaging
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S225
Real-Time Communication of a Clinical Pathway for Upper Gastrointestinal Bleeding through Secure Text Messaging
- 3 August 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (5) , 729-737e1
Comparing American Gastroenterological Association Pancreatic Cyst Management Guidelines with Fukuoka Consensus Guidelines as Predictors of Advanced Neoplasia in Patients with Suspected Pancreatic Cystic Neoplasms
In 2015, the American Gastroenterological Association (AGA) published guidelines to provide recommendations for management of suspected pancreatic cystic neoplasms (PCNs). The aim of this study was to compare efficacy of these with the Fukuoka consensus guidelines in predicting advanced neoplasia (AN) in patients with suspected PCNs. We performed a retrospective study of 239 patients who underwent surgical resection for suspected mucinous PCN at a tertiary care center from 2000 to 2014. Surgical pathology was the gold standard. The AGA and Fukuoka criteria were applied, and their performance in predicting AN, defined as invasive cancer or high-grade dysplasia (HGD), was assessed. Advanced neoplasia was found in 71 of 239 (29.7%) patients (28 invasive cancer, 43 HGD). The Fukuoka “high-risk” (FG-HR) and AGA “high-risk” (AGA-HR) criteria identified patients with AN with sensitivities of 28.2% and 35.2%, specificities of 95.8% and 94.0%, positive predictive values of 74.1% and 71.4%, and negative predictive values of 75.9% and 77.5%, respectively. Overall, there was no significant difference between the guidelines for prediction of AN. There were 7 and 6 cases with invasive cancer, and 23 and 24 cases with HGD missed by the FG-HR and AGA-HR guidelines, respectively. In a retrospective analysis, the AGA guidelines are not superior to the Fukuoka guidelines in identifying AN in suspected PCNs. Both sets of guidelines have fair PPV for detection of AN, which would lead to avoidable resections in patients without AN. Additionally, the high-risk features of both guidelines do not accurately identify all patients with AN.
- 3 August 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (5) , 729-737e1
Comparing American Gastroenterological Association Pancreatic Cyst Management Guidelines with Fukuoka Consensus Guidelines as Predictors of Advanced Neoplasia in Patients with Suspected Pancreatic Cystic Neoplasms
In 2015, the American Gastroenterological Association (AGA) published guidelines to provide recommendations for management of suspected pancreatic cystic neoplasms (PCNs). The aim of this study was to compare efficacy of these with the Fukuoka consensus guidelines in predicting advanced neoplasia (AN) in patients with suspected PCNs. We performed a retrospective study of 239 patients who underwent surgical resection for suspected mucinous PCN at a tertiary care center from 2000 to 2014. Surgical pathology was the gold standard. The AGA and Fukuoka criteria were applied, and their performance in predicting AN, defined as invasive cancer or high-grade dysplasia (HGD), was assessed. Advanced neoplasia was found in 71 of 239 (29.7%) patients (28 invasive cancer, 43 HGD). The Fukuoka “high-risk” (FG-HR) and AGA “high-risk” (AGA-HR) criteria identified patients with AN with sensitivities of 28.2% and 35.2%, specificities of 95.8% and 94.0%, positive predictive values of 74.1% and 71.4%, and negative predictive values of 75.9% and 77.5%, respectively. Overall, there was no significant difference between the guidelines for prediction of AN. There were 7 and 6 cases with invasive cancer, and 23 and 24 cases with HGD missed by the FG-HR and AGA-HR guidelines, respectively. In a retrospective analysis, the AGA guidelines are not superior to the Fukuoka guidelines in identifying AN in suspected PCNs. Both sets of guidelines have fair PPV for detection of AN, which would lead to avoidable resections in patients without AN. Additionally, the high-risk features of both guidelines do not accurately identify all patients with AN.